1
|
Rojas LJ, Lemonovich TL, Marshall SH, Hirschfeld A, Perez F, Bonomo RA. The price of WAR: AMR. JAC Antimicrob Resist 2025; 7:dlaf083. [PMID: 40395972 PMCID: PMC12089782 DOI: 10.1093/jacamr/dlaf083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2025] [Accepted: 04/07/2025] [Indexed: 05/27/2025] Open
Abstract
Background The ongoing conflict in Ukraine has exacerbated the risk of MDR bacterial infections in war-injured patients. Methods We present the case of a Ukrainian soldier who sustained a traumatic explosive injury to the bilateral lower extremities, underwent surgery and subsequently experienced an infection with a carbapenem-resistant Klebsiella pneumoniae. The isolate was subject to genomic WGS. Results This case study describes the successful management of a traumatic injury in a Ukrainian soldier infected with a carbapenem-resistant K. pneumoniae isolated from surgical wounds. WGS revealed a hypervirulent ST147 strain carrying multiple resistance and virulence factors, including bla NDM-1. Treatment with ceftazidime/avibactam and aztreonam was effective. Conclusions Ceftazidime/avibactam and aztreonam is highlighted as a promising regimen for MDR infections in conflict zones.
Collapse
Affiliation(s)
- Laura J Rojas
- Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH, USA
- CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, OH, USA
- Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA
| | - Tracy L Lemonovich
- Division of Infectious Diseases, MetroHealth Medical Center, Cleveland, OH, USA
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - Steven H Marshall
- Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA
| | - Adam Hirschfeld
- Department of Orthopedic Surgery, MetroHealth Medical Center, Cleveland, OH, USA
| | - Federico Perez
- Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - Robert A Bonomo
- Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH, USA
- CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, OH, USA
- Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA
- Departments Pharmacology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, OH, USA
| |
Collapse
|
2
|
Feilong Z, Wenting Y, Binghuai L, Bin C. Dynamic global variation in resistance and hypervirulence of carbapenem-resistant Klebsiella pneumoniae between 2010 and 2023. J Infect 2025; 90:106493. [PMID: 40286916 DOI: 10.1016/j.jinf.2025.106493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2025] [Revised: 04/08/2025] [Accepted: 04/19/2025] [Indexed: 04/29/2025]
Affiliation(s)
- Zhang Feilong
- Peking Union Medical College, Chinese Academy of Medical Sciences, China-Japan Friendship Hospital, Beijing, China
| | - Yang Wenting
- Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China
| | - Lu Binghuai
- Peking Union Medical College, Chinese Academy of Medical Sciences, China-Japan Friendship Hospital, Beijing, China; Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.
| | - Cao Bin
- Peking Union Medical College, Chinese Academy of Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
| |
Collapse
|
3
|
Costescu Strachinaru DI, Ragot C, Stoefs A, Donat N, François PM, Vanbrabant P, Verroken A, Janvier F, Soentjens P. Management and Prevention of Multidrug-Resistant Bacteria in War Casualties. Trop Med Infect Dis 2025; 10:128. [PMID: 40423358 DOI: 10.3390/tropicalmed10050128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2025] [Revised: 05/05/2025] [Accepted: 05/06/2025] [Indexed: 05/28/2025] Open
Abstract
The growing threat of antimicrobial resistance (AMR) is a critical issue for both civilians and the military. With each successive conflict, pathogens become more resistant, making the management of infections in casualties increasingly challenging. To better understand the scope and characteristics of conflict-related AMR, a comprehensive literature search was conducted in the PubMed database in April 2025, using defined search terms related to war casualties and antimicrobial resistance. We screened and included 117 relevant publications, comprising original research articles, reviews, case series, case reports, editorials, and commentaries, published in English or French, with no date restriction. This narrative review synthesizes current evidence on multidrug-resistant bacteria most commonly isolated from war casualties, their associated resistance mechanisms, and the microbiological diagnostic tools available at various levels of the military continuum of care (Roles 1-4). It also presents strategies for preventing cross-contamination and infection in resource-limited combat settings and provides practical, field-adapted recommendations for clinicians, from first responders to specialized care providers, aiming to improve infection management in armed conflict zones and mitigate the spread of AMR.
Collapse
Affiliation(s)
| | - Céline Ragot
- Department of Microbiology, Percy Military Teaching Hospital, 92140 Clamart, France
| | - Anke Stoefs
- Department of Microbiology, Queen Astrid Military Hospital, 1120 Brussels, Belgium
| | - Nicolas Donat
- Burn Center, Percy Military Teaching Hospital, 92140 Clamart, France
- Val de Grâce Academy, 1 Pl. Alphonse Laveran, 75005 Paris, France
| | - Pierre-Michel François
- Medical Component Operational Command, Queen Astrid Military Hospital, 1120 Brussels, Belgium
| | - Peter Vanbrabant
- Center for Infectious Diseases, Queen Astrid Military Hospital, 1120 Brussels, Belgium
- General Internal Medicine, University Hospitals Leuven, 3000 Leuven, Belgium
| | - Alexia Verroken
- Department of Microbiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 1200 Brussels, Belgium
| | - Frédéric Janvier
- Val de Grâce Academy, 1 Pl. Alphonse Laveran, 75005 Paris, France
- Sainte-Anne Military Teaching Hospital BCRM Toulon, 83800 Toulon, France
| | - Patrick Soentjens
- Center for Infectious Diseases, Queen Astrid Military Hospital, 1120 Brussels, Belgium
- Department of Clinical Sciences, Institute of Tropical Medicine, 2000 Antwerp, Belgium
| |
Collapse
|
4
|
Longshaw CM, Dejonge BLM, Yamano Y. Comment on: Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol? J Antimicrob Chemother 2025; 80:1465-1468. [PMID: 40068838 PMCID: PMC12046393 DOI: 10.1093/jac/dkaf074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2025] Open
Affiliation(s)
| | | | - Yoshinori Yamano
- Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd, Osaka, Japan
| |
Collapse
|
5
|
Lofton-Tomenius H, Pang Y, Pallin A, Myktybekova Z, Lelham N, Riesbeck K, Vågesjö E, Roos S, Phillipson M. In Vitro Elimination of Highly Multidrug-Resistant Bacteria by the Lactic Acid Bacterial Drug Candidate ILP100. Infect Dis Ther 2025; 14:1119-1131. [PMID: 40164924 PMCID: PMC12084475 DOI: 10.1007/s40121-025-01137-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2025] [Accepted: 03/14/2025] [Indexed: 04/02/2025] Open
Abstract
INTRODUCTION Multidrug resistance (MDR) has been identified in wound bacterial isolates from Ukrainian war victims treated in Ukraine and across Europe. ILP100, a drug candidate for the treatment of skin wounds, is composed of a Limosilactobacillus reuteri expressing human chemokine CXCL12. In this study, the antimicrobial effects of ILP100 were tested on MDR bacteria isolated from wounds of Ukrainian war victims. METHODS ILP100 was co-cultured with one of the wound pathogens (Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacter cloacae, Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus aureus; 12 non-MDR and 12 MDR isolates) in broth media for 12 h with subsequent survival recovery on agar plates. Additionally, agar plates were precoated with ILP100 at clinical doses (3 vs. 24 h, 1 × 107 CFU/cm2) followed by co-culture with pathogens inoculated in soft agar (1 × 104 CFU/cm2). To compare ILP100 with relevant antibiotics, MDR-inoculated soft agar was applied to plates with standardized ILP100 drops and antibiotic-loaded discs, followed by 18-20 h aerobic incubation at 37 °C. RESULTS Dose-dependent growth inhibition of all pathogens was demonstrated, as 1000:1 and 100:1 (ILP100/isolate) inhibited pathogenic growth up to log 6.4 and log 4.3 CFU/ml, respectively. Potent antimicrobial effects were demonstrated after precoating with ILP100, as pathogen recovery was only demonstrated after 3 h of precoating, only for 10/18 isolates and then only partially. Benchmarking to relevant antibiotic discs resulted in large cleared zones surrounding the ILP100 spots but not the antibiotic discs, demonstrating potent bacterial killing by ILP100-secreted factors. Interestingly, the MDR pathogens were significantly more sensitive to the ILP100 released factors than the non-MDR isolates. CONCLUSION ILP100 effectively eliminates MDR wound pathogens, which reveals a promising strategy for the development of new classes of urgently needed antimicrobials.
Collapse
Affiliation(s)
- Hava Lofton-Tomenius
- Department of Medical Cell Biology, The Science for Life Laboratory, Uppsala University, Uppsala, Sweden
- Ilya Pharma AB, Dag Hammarskjölds väg 36B, 752 37, Uppsala, Sweden
| | - Yanhong Pang
- Ilya Pharma AB, Dag Hammarskjölds väg 36B, 752 37, Uppsala, Sweden
| | - Anton Pallin
- Ilya Pharma AB, Dag Hammarskjölds väg 36B, 752 37, Uppsala, Sweden
| | | | - Ninus Lelham
- Ilya Pharma AB, Dag Hammarskjölds väg 36B, 752 37, Uppsala, Sweden
| | - Kristian Riesbeck
- Clinical Microbiology, Department of Translational Medicine, Lund University, Malmö, Sweden
| | - Evelina Vågesjö
- Department of Medical Cell Biology, The Science for Life Laboratory, Uppsala University, Uppsala, Sweden
- Ilya Pharma AB, Dag Hammarskjölds väg 36B, 752 37, Uppsala, Sweden
| | - Stefan Roos
- Department of Molecular Sciences, Swedish University of Agricultural Sciences, Uppsala Biocenter, Uppsala, Sweden
| | - Mia Phillipson
- Department of Medical Cell Biology, The Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
| |
Collapse
|
6
|
Magda M, Boschloo W, Bettoni S, Fairley D, Russo TA, Giske CG, Tellapragada C, Rooijakkers SH, Riesbeck K, Blom AM. Acinetobacter baumannii Clinical Isolates Resist Complement-Mediated Lysis by Inhibiting the Complement Cascade and Improperly Depositing MAC. J Innate Immun 2025; 17:112-125. [PMID: 39842423 PMCID: PMC11845171 DOI: 10.1159/000543664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2024] [Accepted: 01/15/2025] [Indexed: 01/24/2025] Open
Abstract
INTRODUCTION Acinetobacter baumannii is a gram-negative opportunistic bacterium that causes life-threatening infections in immunocompromised hosts. The complement system is a critical mechanism of innate immunity that protects the human body from bacterial infections. Complement activation leads to the deposition of the membrane attack complex (MAC), which can directly lyse gram-negative bacteria. However, A. baumannii has developed evasion mechanisms to protect itself from complement. METHODS Complement deposition was investigated by flow cytometry and Western blotting. Soluble MAC formation was assessed by ELISA. Bacterial serum resistance was determined by the SYTOX Green Assay. Galleria mellonella was used as an infection model. Genome sequencing revealed virulence genes carried by isolates. RESULTS We examined clinical isolates of A. baumannii and found 11 isolates with MAC deposition and 5 isolates without deposition. Trypsinization of MAC-positive isolates significantly reduced MAC, indicating incorrect insertion, consistent with a lack of lysis of these strains. MAC-negative isolates inhibited alternative pathway activation and were significantly more serum-resistant. These strains were also more virulent in a G. mellonella infection model. Whole genome sequencing revealed that MAC-negative isolates carried more virulence genes, and both MAC-negative and MAC-positive A. baumannii significantly differed in capsule type. Importantly, a correlation was observed between complement inhibition and capsule type (e.g., capsule locus KL171) of MAC-negative bacteria, while the capsule type (e.g., KL230) of MAC-positive A. baumannii was associated with increased sensitivity to MAC-mediated lysis. CONCLUSION Our findings suggest a relationship between capsule type, complement resistance, and host virulence in A. baumannii. INTRODUCTION Acinetobacter baumannii is a gram-negative opportunistic bacterium that causes life-threatening infections in immunocompromised hosts. The complement system is a critical mechanism of innate immunity that protects the human body from bacterial infections. Complement activation leads to the deposition of the membrane attack complex (MAC), which can directly lyse gram-negative bacteria. However, A. baumannii has developed evasion mechanisms to protect itself from complement. METHODS Complement deposition was investigated by flow cytometry and Western blotting. Soluble MAC formation was assessed by ELISA. Bacterial serum resistance was determined by the SYTOX Green Assay. Galleria mellonella was used as an infection model. Genome sequencing revealed virulence genes carried by isolates. RESULTS We examined clinical isolates of A. baumannii and found 11 isolates with MAC deposition and 5 isolates without deposition. Trypsinization of MAC-positive isolates significantly reduced MAC, indicating incorrect insertion, consistent with a lack of lysis of these strains. MAC-negative isolates inhibited alternative pathway activation and were significantly more serum-resistant. These strains were also more virulent in a G. mellonella infection model. Whole genome sequencing revealed that MAC-negative isolates carried more virulence genes, and both MAC-negative and MAC-positive A. baumannii significantly differed in capsule type. Importantly, a correlation was observed between complement inhibition and capsule type (e.g., capsule locus KL171) of MAC-negative bacteria, while the capsule type (e.g., KL230) of MAC-positive A. baumannii was associated with increased sensitivity to MAC-mediated lysis. CONCLUSION Our findings suggest a relationship between capsule type, complement resistance, and host virulence in A. baumannii.
Collapse
Affiliation(s)
- Michal Magda
- Department of Translational Medicine, Lund University, Malmö, Sweden
| | - Wendy Boschloo
- Department of Translational Medicine, Lund University, Malmö, Sweden
| | - Serena Bettoni
- Department of Translational Medicine, Lund University, Malmö, Sweden
| | - Derek Fairley
- Department of Microbiology, Belfast Health and Social Care Trust, Belfast, UK
| | - Thomas A. Russo
- Veterans Administration Western New York Healthcare System, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University Buffalo, Buffalo, NY, USA
| | | | | | - Suzan H.M. Rooijakkers
- Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| | - Kristian Riesbeck
- Department of Translational Medicine, Lund University, Malmö, Sweden
| | - Anna M. Blom
- Department of Translational Medicine, Lund University, Malmö, Sweden
| |
Collapse
|